TY  - JOUR
A1  - Burgard, Niklas
A1  - Kienitz, Melanie
A1  - Jourdan, Claudia
A1  - Rüttermann, Stefan
T1  - The influence of modified experimental dental resin composites on the initial in situ biofilm - a triple-blinded, randomized, controlled split-mouth trial
T2  - Polymers
N2  - The purpose of the study was to investigate the bacterial viability of the initial biofilm on the surface of experimental modified dental resin composites. Twenty-five healthy individuals with good oral hygiene were included in this study. In a split-mouth design, they received acrylic splints with five experimental composite resin specimens. Four of them were modified with either a novel polymeric hollow-bead delivery system or methacrylated polymerizable Irgasan (Antibacterial B), while one specimen served as an unmodified control (ST). A delivery system based on Poly-Pore® was loaded with one of the active agents: Tego® Protect 5000 (Antiadhesive A), Dimethicone (Antiadhesive B), or Irgasan (Antibacterial A). All study subjects refrained from toothbrushing during the study period. Specimens were detached from the splints after 8 h and given a live/dead staining before fluorescence microscopy. A Friedman test and a post hoc Nemenyi test were applied with a significance level at p < 0.05. In summary, all materials but Antibacterial B showed a significant antibacterial effect compared to ST. The results suggested the role of the materials’ chemistry in the dominance of cell adhesion. In conclusion, dental resin composites with Poly-Pore-loaded active agents showed antibacterial effectiveness in situ.
KW  - antibacterial composites
KW  - antiadhesive composites
KW  - Poly-Pore
KW  - split-mouth
KW  - clinical trial
KW  - live/dead staining
KW  - bacterial viability
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62601
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-626018
SN  - 2073-4360
N1  - This research was supported by the DFG Deutsche Forschungsgemeinschaft, Bonn, Germany (project no. RU 825/3-1).
VL  - 13
IS  - 16, art. 2814
SP  - 1
EP  - 13
PB  - MDPI
CY  - Basel
ER  -